Cinnamycin (Synonyms: Lanthiopeptin,NSC 71936,Ro 09-0198) |
Catalog No.GC13811
One-Click Copy Product Info
|
tricyclic antibiotic
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 110655-58-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cinnamycin is a tricyclic antibiotic.
Cinnamycin, a tetracyclic lantibiotic, is produced from S. cinnamoneus containing four unusual amino acids: mesolanthionine, erythro-β-hydroxyaspartic acid, threo-β-methyllanthionine and lysinoalanine.
In vitro: A previous study indicated that cinnamycin could exclusively bind to ethanolamine phospholipids, such as PE and ethanolamine plasmalogen. Model membrane study showed that the binding of cinnamycin to PE-containing liposomes was dependent on membrane curvature. The binding of cinnamycin to multilamellar liposomes induced tubulation of membranes, as demonstrated by electron microscopy and small-angle x-ray scattering [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: A retrospective survey of patients treated with clindamycin for a soft tissue infection was conducted to evaluated whether the incidence of serious side effects was sufficient to preclude the use of this antibiotic. Thirteen patients were found to have severe diarrhoea and 2 of these required inpatient treatment. Certain limitations of the use of clindamycin were suggested but, it was concluded that cinnamycin still has a useful role to play in the treatment of acute soft tissue infection [2].
References:
[1] Iwamoto K, Hayakawa T, Murate M, Makino A, Ito K, Fujisawa T, Kobayashi T. Curvature-dependent recognition of ethanolamine phospholipids by duramycin and cinnamycin. Biophys J. 2007 Sep 1;93(5):1608-19.
[2] Wilson DH. Clindamycin in the treatment of soft tissue infections: a review of 15 019 patients. Br J Surg. 1980 Feb;67(2):93-6.
| Cas No. | 110655-58-8 | SDF | |
| Synonyms | Lanthiopeptin,NSC 71936,Ro 09-0198 | ||
| Chemical Name | L-cysteinyl-L-arginyl-L-glutaminyl-D-cysteinyl-L-cysteinyl-3-aminoalanyl-L-phenylalanylglycyl-L-prolyl-L-phenylalanyl-(2S,3S)-2-amino-3-mercaptobutanoyl-L-phenylalanyl-L-valyl-L-cysteinyl-(3R)-3-hydroxy-L-a-aspartylglycyl-L-asparaginyl-(2S,3S)-2-amino-3-m | ||
| Canonical SMILES | O=C([C@H](C(C)C)NC([C@H](CC1=CC=CC=C1)NC([C@@H]([C@H](C)SC[C@H](NC([C@H](N2)CSC3)=O)C4=O)NC([C@H](CC5=CC=CC=C5)NC([C@H]6N(C(CNC([C@@H](NC([C@H](CNCCCC[C@@H](C(O)=O)N7)N4)=O)CC8=CC=CC=C8)=O)=O)CCC6)=O)=O)=O)=O)N[C@@H]3C(N[C@@H]([C@@H](O)C(O)=O)C(NCC(N | ||
| Formula | C89H125N25O25S3 | M.Wt | 2041.3 |
| Solubility | Soluble in ethanol;Soluble in DMSO;Soluble in dimethyl formamide | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 489.9 μL | 2.4494 mL | 4.8988 mL |
| 5 mM | 98 μL | 489.9 μL | 979.8 μL |
| 10 mM | 49 μL | 244.9 μL | 489.9 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)